IA
VYNT

IFP Advisors’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

IFP Advisors’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-13
Closed -$8K – 4262
2017
Q1 		$8K Buy
+13
New +$4.63K ﹤0.01% 3074

Other funds holding VYNT

PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Fairbanks Capital Management Rancho Santa Fe, California $160M AUM 14.36% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
TDC
Thompson Davis & Co Richmond, Virginia $150M AUM 32.35% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DM
Diker Management New York $112M AUM 59.78% 1-Year Est. Return

IFP Advisors's VYNT Position: Q2 2017 in Review

IFP Advisors sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q2 2017, closing a stake of 13 shares — an estimated $8K sold.

IFP Advisors first reported a position in VYNT in Q1 2017 and held it in 1 quarter. The position peaked at $8K in Q1 2017. 28 funds tracked by Wall St. Rank hold VYNT as of Q2 2017.

  • IFP Advisors reported no remaining Vyant Bio, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • IFP Advisors sold 13 Vyant Bio, Inc. Common Stock shares in Q2 2017, an estimated $8K.
  • IFP Advisors first reported a position in Vyant Bio, Inc. Common Stock in Q1 2017 and held it in 1 quarter.
  • IFP Advisors's Vyant Bio, Inc. Common Stock position peaked at $8K in Q1 2017.
  • 28 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q2 2017.

Based on IFP Advisors's 13F filing for Q2 2017, filed 31 Jul 2017.